hyoscyamine has been researched along with buspirone in 2 studies
Studies (hyoscyamine) | Trials (hyoscyamine) | Recent Studies (post-2010) (hyoscyamine) | Studies (buspirone) | Trials (buspirone) | Recent Studies (post-2010) (buspirone) |
---|---|---|---|---|---|
99 | 1 | 55 | 2,096 | 351 | 382 |
Protein | Taxonomy | hyoscyamine (IC50) | buspirone (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.025 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 1.75 | |
Angiotensin-converting enzyme | Homo sapiens (human) | 0.024 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.323 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 2.125 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 4.16 | |
D | Rattus norvegicus (Norway rat) | 0.12 | |
D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.12 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0266 | |
D(2) dopamine receptor | Bos taurus (cattle) | 4 | |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 4.16 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.077 | |
D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.12 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 2.286 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.016 | |
D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.12 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 2.125 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.044 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.75 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 4.16 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.2055 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.9811 | |
Alpha-2A adrenergic receptor | Bos taurus (cattle) | 0.025 | |
Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.7 | |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.2666 | |
Lysosomal alpha-glucosidase | Bos taurus (cattle) | 0.03 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
2 other study(ies) available for hyoscyamine and buspirone
Article | Year |
---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |